Drug makers promise health plans a discount, called a rebate, in return for good coverage of a drug. Every quarter the plan, or the company that runs its drug benefit, sends a bill for those rebates with a file of every prescription behind it. Rebate claims validation is checking that bill, prescription by prescription, against the contract before the maker pays it.
This guide is for anyone who checks, signs, books or pays rebate invoices: rebate operations analysts and leads, contract operations, gross-to-net accounting, government pricing, market access and finance leaders deciding whether to automate the work. No background needed.
Imagine you are the rebate operations lead at a mid-size biotech, Northwind Bio. It is Wednesday, October 7, 2026, and a payer, Harbor Union Rx, has just sent its second-quarter Medicare Part D rebate invoice (Part D is Medicare's prescription drug benefit): 13 lines, 36,940 prescriptions, $4,284,591, due November 6. Line 3 bills 276 cartons of your drug Veltrimab at the 25% rate for a preferred brand, $302,220. The rate matches your contract's rate table, so a rate check passes it.
Then you read clause 4.2(b): the plan earns 25% only if Veltrimab sat on the preferred tier, the level where patients pay less, for the whole quarter, with no step therapy, a rule that patients try another drug first. Otherwise it earns 8%. Harbor Union's own formulary file, the list of which drugs each plan covers and on what terms, moved Veltrimab on that plan on April 1, the first day of the quarter.
Invoice · line 3, plan S7742-004
Units
276 cartons
Rate billed
25% of list price
List price
$4,380 a carton
Billed
$302,220
Payer's formulary file · Q2 2026
Effective
04/01/2026
Tier
4, non-preferred
Edit
Step therapy
Rate earned
8%: $96,710
$302,220 as billed$96,710 owedon one line, proved by the payer's own file.
Two more lines fail the same way. Add prescriptions filled under 340B, a federal discount program for safety-net hospitals and clinics, prescriptions already paid last quarter and an administrative fee above its cap, and $655,423 of the invoice is disputable, each amount with its clause and its rows. You pay the undisputed $3,629,168 on time.
Careful validation catches the rate that was right on the table and wrong for the quarter, before the money leaves.
Checking a payer's rebate invoice: contracts, formulary position, claims and the 2026 rules
The invoice, the contract, the formulary test, 340B and Medicaid overlap, Best Price, the errors and the market, explained without selling anything. If you are new to drug rebates, start here.
01 · In plain words
Drug rebates in plain words: a discount promised up front, billed a quarter later, on conditions
A drug has a list price. In the United States that list price is rarely what the maker keeps. To win good coverage, the maker signs a contract with a health plan or with a pharmacy benefit manager (PBM), the company that runs a plan's drug benefit. The contract says: put our drug on a favorable tier of your formulary (your covered-drug list, where each tier sets what patients pay), and we will pay you back a percentage of the list price on each prescription. That payment back, "a retrospective payment made by the seller to the buyer" in the words of the actuarial firm Milliman, is a rebate.1
The pharmacy fills the prescription in April. Months later, the plan or PBM adds up the quarter's prescriptions and sends the maker an invoice with a data file behind it, often hundreds of thousands of rows. The maker has a set number of days to pay. Late payments can carry what IQVIA's consultants call "a hefty penalty fee".2 So a small team has a few weeks to decide whether a very large bill is right.
Checking the bill means asking five questions of every line. Was this contract in force, with which amendment? Was this plan covered by it? Did the plan give the drug the place on its formulary, its formulary position, that the rebate depends on, in that month? Should each prescription be on this bill at all, or does it belong to 340B (a federal discount program for safety-net hospitals and clinics), a State's invoice under Medicaid (the public health program for people with low incomes) or last quarter's bill? And does the arithmetic work, at the list price of that date?
The work is called rebate claims validation, or script-level validation, because it goes down to each prescription (a "script"). Teams also call it rebate invoice validation, managed care rebate processing or pharmaceutical rebate reconciliation. The money is large. Drug Channels Institute estimates that makers' total reductions from gross sales at list price to net sales on brand drugs reached $416 billion in 2025, with rebates to payers the largest part.3 Errors move real money in both directions, and the party who pays is the one who has to find them.
One Part D rebate, from signed contract to paid invoice
The maker and the payer signNorthwind Bio and Harbor Union Rx agree 25% on the preferred tier for a whole quarter, 8% otherwise, under contract HUR-2025-022.
The plan sets its formularyOn April 1, 2026 three of Harbor Union's plans move Veltrimab to Tier 4 with step therapy. The other three keep it on Tier 3.
Pharmacies fill prescriptionsBetween April and June, 36,940 prescriptions are filled across six plans. Nothing about the rebate happens at the counter.
The invoice arrives and is validatedOn October 7 the bill comes: 13 lines, $4,284,591, due in 30 days. This is where the $655,423 is caught, or paid.
The maker pays, disputes and trues upThe undisputed amount goes out, a letter cites each clause, and accounting corrects its estimate of what the quarter would cost.
Step 4 is the subject of this guide. Part D is Medicare's prescription drug benefit. The people, companies and figures in this example are fictional.
Four things about rebate invoices that surprise newcomers
A correct rate can still be the wrong rate
The rate on the line can match the contract's table exactly. Whether the plan earned that rate depends on where the drug sat on its formulary that month, and the invoice does not say.
The proof usually sits in the payer's own file
The industry's rebate data standard covers utilization, plan, formulary, market basket and reconciliation files.4 The formulary file is often already on the desk. It is rarely matched line by line.
Medicaid gives you a way to pay first and argue later
A long-standing federal notice says a maker may pay a State invoice in full on time and dispute it afterward, which removes interest on the payment. If the dispute later cuts the bill, the State credits it with interest.5
Only some rebates reach Medicaid's Best Price
Best Price, the lowest net price a maker offers in a quarter, feeds the Medicaid rebate. The regulation leaves out Part D prices and PBM rebates, with two named exceptions for PBM rebates. Rebates to a health plan can count.6 So the same mistake can be harmless in one channel and costly in another.
Four terms every rebate invoice uses: invoice, utilization file, formulary position, WAC
Rebate invoice
The payer's quarterly bill to the maker: one line per product, plan or rate, with a total due.
Utilization file
The data behind the bill: one row per prescription, with drug, plan, pharmacy, fill date and quantity.
Formulary position
Where a plan puts a drug on its covered list: the cost-sharing tier, and any hurdle such as prior authorization or step therapy.
WAC
Wholesale acquisition cost, the drug's list price. Most rebate rates are a percentage of it.
What rebate claims validation checks: from an invoice total down to one prescription
In shortValidation can happen at three depths: the invoice total, the plan and rate, and each prescription. Most money that leaks is visible only at the two lower depths. Each payer channel adds its own rules, so a Part D line, a commercial line and a Medicaid line need different checks even when the drug is the same.
Depth 1
The invoice ties out
Do the lines add to the total? Do the data files add to the lines? The first test stops files that are incomplete or that overlap. Harbor Union's two files tie to $4,284,591.
Depth 2
The line matches the contract
Is each plan in the contract? Is the rate the one in force? Did the plan hold the position the rate requires? A rate check passes Line 3 at this depth unless the position is tested as well.
Depth 3
The prescription belongs here
Is it a 340B fill? Is it also on a State Medicaid invoice? Was it billed last quarter? Is it inside the look-back window, the limit on how far back a claim can be billed? Harbor Union's bill holds 578 such prescriptions among 36,940.
Two terms come up constantly. A script scrubber is software that runs depth-three checks on a utilization file before the rebate is calculated. Revenue management is the larger system that holds contracts and calculates what is owed. IQVIA's 2023 review of managed care rebate work names one gap between them: a scrubber can check that a plan exists and a product exists, each on its own, so a plan and product pair the contract does not cover passes until the later calculation.2
Commercial, Part D and Medicaid lines answer to different rules
Contracts govern commercial and Part D rebates; statutes govern State Medicaid
Where each duty comes from, by the kind of payer sending the invoice
Usually noneBy contractBy statute or rule
The ratePosition test340B claims outPay and dispute termsCommercial PBM or planBy contractBy contractBy contractBy contractMedicare Part D sponsor or PBMBy contractBy contractBy contractBy contractManaged Medicaid plan, supplementalBy contractBy contractBy statute or ruleBy contractState Medicaid invoiceBy statute or ruleUsually noneBy statute or ruleBy statute or ruleEmployer coalitionBy contractBy contractBy contractBy contract
Our reading of the sources7,8,5,9 · Our reading of the statutes and of the agreements the Government Accountability Office (GAO) reviewed. Your own agreements decide the details.
Show the numbers
The rate
Position test
340B claims out
Pay and dispute terms
Commercial PBM or plan
By contract
By contract
By contract
By contract
Medicare Part D sponsor or PBM
By contract
By contract
By contract
By contract
Managed Medicaid plan, supplemental
By contract
By contract
By statute or rule
By contract
State Medicaid invoice
By statute or rule
Usually none
By statute or rule
By statute or rule
Employer coalition
By contract
By contract
By contract
By contract
Channel
Who bills
What sets the rebate
The check people forget
Commercial
PBM, its group purchasing arm, or a health plan
Contract: rate grid by formulary position, often with price protection and fees
Opted-out employer groups on a contract schedule
Medicare Part D
Plan sponsor (the insurer offering the plan) or its PBM, by plan benefit package (one Part D plan under the sponsor's contract)
Contract: tier, restrictions, competitors on the tier7
A tier move approved mid-year, plan by plan
Managed Medicaid
The private plan that runs Medicaid benefits for the State, under its own supplemental agreement
Contract, on top of the State's statutory rebate on the same drug
Claims also on the State's invoice
State Medicaid
Each State Medicaid agency
Statute: the greater of 23.1% of average manufacturer price (what wholesalers and retail pharmacies pay the maker, on average) or that price less Best Price, plus inflation8,10
Disputes settle on units, never on what the State paid the pharmacy5
Employer coalition
The coalition or its administrator
Contract, usually a simpler base rate
Members who left the coalition mid-year
The Inflation Reduction Act's Manufacturer Discount Program, which replaced the Part D coverage gap discount in 2025, and negotiated Medicare prices are separate flows with their own invoices. This guide covers rebates billed by payers under a contract, and State Medicaid invoices where they overlap.3,11
03 · The rules and their dates
The rules around rebate invoices, and what moved between 2024 and 2026
Status as of November 2026
In shortNo federal rule says how to validate a commercial or Part D rebate invoice. The contract does. Federal law sets the Medicaid rebate, bans duplicate discounts with 340B, limits when a Part D plan can change its formulary and defines Best Price. Recent changes reshape the money flow: the uncapped Medicaid rebate, negotiated Medicare prices, a contested 340B rebate pilot and a 2026 law on PBM pay.
Who is who: CMS (Centers for Medicare & Medicaid Services) runs Medicare and Medicaid, and HRSA (Health Resources and Services Administration) runs 340B. The FTC (Federal Trade Commission) enforces competition law, and NCPDP (National Council for Prescription Drug Programs) sets pharmacy data standards.
Seven changes since 2024 alter what a rebate invoice carries
Jan 1, 2024Medicaid rebate cap ends
Rebates for periods from this date can exceed 100% of average manufacturer price.
Jan 2025Part D redesign
A $2,000 out-of-pocket cap, higher plan liability and the Manufacturer Discount Program.
Jan 1, 2026First negotiated Medicare prices
Ten Part D drugs. Rebate deals on those drugs change shape.
Jan 2026GENEROUS model starts
A voluntary CMS Medicaid model; States bill supplemental rebates quarterly.
Feb 2026PBM law and an FTC order
The 2026 appropriations act passes. A proposed FTC order addresses high-list-price versions; a second PBM's followed in July.
Nov 2026Where things stand
Revised 340B pilot under challenge in Maine; delay bill in the House.
Jan 1, 2027Next 15 Medicare prices, 340B pilot date
The revised rebate pilot takes effect if it survives.
Jan 1, 2028Part D PBM pay delinked
PBMs paid by flat service fee; rebates fully passed to sponsors.
Rates, tier conditions, exclusions, fees, look-back, payment and dispute terms. GAO found every sponsor and maker it reviewed tied rebates to the preferred tier.7
Private; amended often
42 CFR 423.120(e), (f)
A Part D sponsor needs CMS's process for a negative formulary change (one that makes a drug harder or costlier to get) and gives "at least 30 days" notice, or a month's supply at refill, with an exception for immediate substitutions. So a tier can change inside a plan year, through that process.20
Current
42 USC 1396r-8
States report utilization within 60 days after the quarter; the maker pays "not later than 30 days after" receipt. Basic rebate: 23.1% of average manufacturer price or that price less Best Price, if greater.8,10
Current; uncapped from 2024
CMS interest page
"manufacturers have 37 calendar days to pay rebates before interest begins to accrue", running from the invoice postmark.21
Updated June 10, 2026
CMS Release No. 27
Disputes are "identified on an NDC/quarter/reason basis" (NDC is the national drug code). Pay the undisputed part on time. A low reimbursement to the pharmacy is no ground for dispute.5
March 5, 1997; still the plain statement
42 USC 256b(a)(5)
Bars a duplicate discount with a Medicaid rebate and lets a manufacturer audit a covered entity (a hospital or clinic in the 340B program) under set procedures.9 Commercial and Part D exclusions of 340B claims come from your contracts.
Current
42 CFR 447.505, 447.510
What counts toward Best Price; revisions within 12 quarters; reports certified by the CEO, CFO or a delegate; records kept 10 years.6,22
Current
42 CFR 1001.952(h)
The discount safe harbor, which protects qualifying discounts under the federal anti-kickback law, defines a rebate as a discount "the terms of which are fixed and disclosed in writing". The text also carries an exclusion for Part D reductions, in (h)(5)(viii). Congress delayed it, most recently in the Inflation Reduction Act, and it is stayed until January 1, 2032.23,24
Part D exclusion stayed to January 1, 2032
45 CFR 164.514(b)(2)
The HIPAA de-identification list covers dates other than the year, places below State level, and "any other unique identifying number". A claim row with a prescription number, fill date and pharmacy deserves a privacy review.25
Current
15 USC 7262
Public companies assess "the effectiveness of the internal control structure and procedures" for financial reporting each year. Rebate accruals and payments sit inside that scope.26
Current
Which quality rules do not apply. Rebate invoices are commercial finance. GxP (the good-practice rules for drug quality), 21 CFR Part 11 and EU Annex 11 govern quality and regulated records in development and manufacturing, and FDA's Computer Software Assurance guidance covers software in medical device production and quality systems, so all of them sit outside this work. FDA's January 2025 draft guidance on AI covers information "intended to support regulatory decision-making regarding safety, effectiveness, or quality", and a payment decision falls outside it.27 The controls that matter here are financial reporting controls, price reporting records and your data agreements with payers.
The second 340B rebate pilot, its dates and its challengers
The 340B program lets safety-net hospitals and clinics buy drugs at steep discounts. In 2025 HRSA approved a pilot that would let some makers pay the 340B discount as a rebate after the sale, instead of up front. A federal court in Maine stopped that version. The revised pilot covers only drugs on the Medicare negotiation lists for 2026 and 2027, which the notice puts at less than 5.5% of total 340B sales on 2025 data.13
Blocked once and sued again, the 340B rebate pilot is still set for January 1, 2027
Dec 29, 2025Federal judge blocks the first pilot
A court in Maine stops the pilot approved in 2025.
Feb 10, 2026Court vacates and remands
The court sets aside the notices and approvals and returns them to the agency.
Aug 3, 2026Revised notice published
HRSA publishes the second version.
Oct 9, 2026Hospitals sue in Maine
The American Hospital Association, the Maine Hospital Association and four hospitals sue to stop it. Drug makers have moved to join the case.
Nov 3, 2026No ruling or vote reported that we found
Trade press still showed the case pending on October 22.
Jan 1, 2027Approved makers' plans take effect
Unless a court or Congress stops them first.
Dec 31, 2028End date in a House bill
H.R. 10770, a bipartisan bill, would keep 340B discounts up front through this date.
Check the docket before planning on either outcome. The pilot would create claim data about 340B fills, and HRSA says it will use that data to assess and prevent duplicate discounts. The notice also says makers and their platforms should not use the data for any purpose the pilot does not identify, so ask counsel before planning to use it in your commercial or Part D checks.13
The 2026 PBM law: effective dates and what stays
Part D · January 1, 2028
PBMs may take only a flat bona fide service fee, a genuine payment for work done, for Part D work, and manufacturer rebates are allowed only if fully passed through to the sponsor. Within 30 days of finalizing a manufacturer contract that makes payments on one drug contingent on the coverage, placement or utilization management of other drugs, the PBM must explain it in writing to the sponsor. CMS proposed rules to carry this out on October 20, 2026, with comments due December 15.16,29
ERISA plans · about January 1, 2029
PBMs must pass "100 percent of rebates, fees, alternative discounts, and other remuneration" to employer plans covered by ERISA, the federal employee benefits law, about 30 months after enactment for calendar-year plans. Bona fide service fees stay with the PBM. Larger plans get semiannual reports.16
Both provisions change who keeps the money and what documentation exists. Rebates continue, and a maker checks an invoice the same way.
Separately, the FTC's proposed order of February 4, 2026 would stop one large PBM from favoring "high wholesale acquisition cost versions of a drug over identical low wholesale acquisition cost versions" on its standard formularies. The release shows it as proposed, open for public comment.17 The FTC announced a similar proposed order with a second PBM on July 14, 2026.18 On November 3, 2026 the FTC's case page, last updated July 14, listed the matter as pending and showed no final order for either company.30
04 · The files
What arrives with a rebate invoice: the utilization file, the formulary file and the layouts that break
In shortA rebate invoice is a short summary on top of a large data file. An industry standard exists for the data, and many payers depart from it. Five sources answer almost every question: the invoice, the utilization file, the contract with its amendments, the payer's formulary file, and outside lists such as the federal 340B database and State invoices.
Source
What is in it
Where it comes from
What can go wrong
Invoice
Lines by product and plan; units, rate, amount; administrative fee; total and due date
Payer portal or email, often a PDF
Total that does not tie to the files
Utilization file
One row per prescription: drug code, plan, pharmacy, fill date, prescription number, quantity
NCPDP layout or the payer's own
New layouts with no notice; overlapping main and adjustment files2
Rebate agreement and amendments
Rates, tier conditions, exclusions, fees, look-back, schedules of plans and opted-out groups
Effective date, plan, tier, restriction, and sometimes competitors
Payer, often monthly; or a coverage data provider
Not matched to lines; one plan's rule applied to another
340B database and 340B flag
Covered entities and contract pharmacies by date; NCPDP Submission Clarification Code 20 on the claim
The federal agency's public database; the pharmacy
Date of dispensing ignored; flag missing
State Medicaid invoices
Quarterly units by drug code; sometimes claim-level data
States
Summary data that cannot match a claim
The standard is NCPDP's "Manufacturer Rebates Utilization, Plan, Formulary, Market Basket, and Reconciliation Flat File Standard", which supports electronic submission of rebate data to manufacturers' contracting groups.4 It is voluntary in practice.
IQVIA reports that PBMs "can use different versions of the NCPDP format or decide to use their own conceived layouts", that format changes usually arrive with no notice, and that the problem often surfaces only when a load fails or a calculation comes out wrong.2 One vendor's brief calls payer rebate data "low-quality and inconsistent".31 That is a seller's phrase, and it matches what the consultants describe.
A few high-priced prescriptions can carry a large share of the rebate dollars
Veltrimab is 4% of Harbor Union's prescriptions and 36% of its dollars
Invoice dollars, Harbor Union Q2 2026 Part D invoice
$4.28Minvoiced
Dravenzo, 35,544 prescriptions$2.1M
Veltrimab, 1,396 prescriptions$1.5M
Administrative fee$705.8K
Fictional example from this guide
Show the numbers
Part
Value
Dravenzo, 35,544 prescriptions
$2.1M
Veltrimab, 1,396 prescriptions
$1.5M
Administrative fee
$705.8K
A high-priced specialty drug has few prescriptions and large dollars per row. A sample of rows tests the common drug well and the expensive one badly, which is one reason sampling has limits in this work.
Which source settles which rebate check
No single file proves a line; the formulary file is the one most often left out
Our reading of the sources2,4 · Our reading; a duplicate check also needs earlier quarters' files, and quantity needs the product's labeled dosing.
Show the numbers
Invoice
Claims file
Contract
Formulary file
Outside lists
Totals tie
Needed
Needed
Not needed
Not needed
Not needed
Plan in contract
Needed
Needed
Needed
Not needed
Not needed
Rate and fee
Needed
Not needed
Needed
Not needed
Not needed
Formulary position
Needed
Not needed
Needed
Needed
Not needed
340B overlap
Not needed
Needed
Needed
Not needed
Needed
Medicaid overlap
Not needed
Needed
Needed
Not needed
Needed
Duplicates
Not needed
Needed
Not needed
Not needed
Not needed
Look-back and territory
Not needed
Needed
Needed
Not needed
Not needed
Quantity
Not needed
Needed
Not needed
Not needed
Needed
05 · Formulary position
Formulary compliance validation: testing the position a plan held, month by month
In shortMost brand rebates are paid in exchange for a place on the formulary, and that place can change inside a plan year. A rate check passes these lines, because the rate is on the contract. Only a test of the position held, plan by plan and month by month, shows that a plan earned a lower rate.
GAO read 2020 agreements between six makers and six Part D sponsors or their PBMs, covering 24 brand drugs.7 Every sponsor and maker had agreements that based rebates on placement on the tier with the lowest cost sharing relative to competitors. Every one also based amounts in part on how many competitors shared the tier. Some agreements "specified that manufacturers would only pay rebates if their drug was on the preferred formulary tier and not subject to any restrictions".7
Every Part D sponsor and maker GAO reviewed tied rebates to formulary position
Sponsors and makers with each kind of rebate condition, in GAO's review of 2020 agreements
Drug on the preferred formulary tierall100%
Fewer competitors on the preferred tierall100%
Competitor restricted or excludedall100%
Bundled with the maker's other drugsat least half50%
Source7 · GAO reviewed agreements for 24 brand drugs. 'At least half' is drawn at 50.
Show the numbers
Rebate condition
Share of sponsors and makers
Drug on the preferred formulary tier
100%
Fewer competitors on the preferred tier
100%
Competitor restricted or excluded
100%
Bundled with the maker's other drugs
50%
Why tier moves happen in the middle of a Part D year
A Part D formulary can change during the year, under rules. Under 42 CFR 423.120, a sponsor may make a "negative formulary change" through a request to CMS, and must give written notice "at least 30 days prior to the date the change becomes effective", or a month's supply and the notice at refill, naming whether a drug is "moving it to a higher cost-sharing tier" or getting a more restrictive requirement.20 These notices are public. One PBM's June 2026 notice lists removals of brand drugs after a generic arrived, with effective dates in May.32
Commercial plans can change more freely. IQVIA says plans "can switch from one formulary to another or remove/add restrictions that affect rebate eligibility", that this is "even more complicated if it takes effect mid-period", and that there is "No simple way to reprocess a subset of scripts" once they are paid.2
Harbor Union's Veltrimab position, plan by plan, January to June 2026
Three of six plans lost the preferred position on April 1, and the invoice stayed at 25%
Did each plan hold Tier 3 with no restriction? Veltrimab, fictional Harbor Union file
Not heldHeld
JanFebMarAprMayJunS7742-001HeldHeldHeldHeldHeldHeldS7742-002HeldHeldHeldHeldHeldHeldS7742-004HeldHeldHeldNot heldNot heldNot heldS7742-007HeldHeldHeldNot heldNot heldNot heldS7742-009HeldHeldHeldHeldHeldHeldS7742-011HeldHeldHeldNot heldNot heldNot held
Fictional example from this guide · Contract clause 4.2(b) tests the whole quarter, so one month out is enough to lose the rate.
Show the numbers
Jan
Feb
Mar
Apr
May
Jun
S7742-001
Held
Held
Held
Held
Held
Held
S7742-002
Held
Held
Held
Held
Held
Held
S7742-004
Held
Held
Held
Not held
Not held
Not held
S7742-007
Held
Held
Held
Not held
Not held
Not held
S7742-009
Held
Held
Held
Held
Held
Held
S7742-011
Held
Held
Held
Not held
Not held
Not held
Variance on a position failure = units × (rate billed − rate earned) × WAC 632 cartons × (25% − 8%) × $4,380 = $470,587
Three red lines shrink by 68% at the rate the position earned
Billed against owed, Veltrimab lines 3, 4 and 6 of the example invoice
Billed at 25%Owed at 8%
Line 3 · S7742-004 · 276 cartons$302.2K$96.7K
Line 4 · S7742-007 · 198 cartons$216.8K$69.4K
Line 6 · S7742-011 · 158 cartons$173K$55.4K
Fictional example from this guide
Show the numbers
Billed at 25%
Owed at 8%
Line 3 · S7742-004 · 276 cartons
$302.2K
$96.7K
Line 4 · S7742-007 · 198 cartons
$216.8K
$69.4K
Line 6 · S7742-011 · 158 cartons
$173K
$55.4K
Exclusivity, prior authorization and competitors joining a tier
Exclusivity
A competitor joins mid-month
In the fictional Crestline Rx contract, a 6% extra rebate applies only in months when Veltrimab is the sole preferred brand. A competing brand, Ostravel, joins Tier 2 on June 12, so June fails: 5,440 claims and $1,429,632 of exclusivity rebate fall away.
Restriction
Prior authorization appears
In the fictional Granite contract the rate is 22% with no prior authorization and 18% with it. Prior authorization applied in April and May, so those two lines are recalculated at the lower rate.
Parity
Two brands, one tier
GAO found rebates often rise as fewer competitors share the preferred tier.7 A file that names tier only can miss a parity change. Check that the formulary file carries what your clause tests.
Read the clause for its time test. "For the whole quarter", "in any month", "on the first day of the quarter" and "at any time in the quarter" produce different answers from the same file. Write the test for each clause into your validation rules, and have contract operations confirm it.
06 · The recalculation
Recalculating a rebate invoice line by line: billed, owed and variance on $4.28 million
In shortRebuild every line from eligible units, the rate earned and the list price in effect. The result is three columns the whole team can read: billed, owed and variance. The total variance on the fictional Harbor Union invoice is $655,423, in four causes.
Owed on a line = eligible units × rate earned × WAC on the contract's price date Variance = billed − owed
Line
What was billed
What the check found
Owed
Variance
1 · Veltrimab -001
318 cartons at 25%: $348,210
28 claims excluded, 290 left
$317,550
$30,660
3 · Veltrimab -004
276 cartons at 25%: $302,220
Tier 4 with step therapy from April 1: 8%
$96,710
$205,510
7 · Dravenzo -001
8,120 bottles at 14%: $468,362
200 claims excluded, 7,920 left
$456,826
$11,536
9 · Dravenzo -004
7,010 bottles at 14%: $404,337
Every claim ties
$404,337
$0
13 · Administrative fee
3.4% of $20,758,608 of WAC: $705,793
Clause 5.1 caps the fee at 3%
$622,758
$83,034
Fictional example, five of 13 lines. WAC is $4,380 a carton for Veltrimab and $412 a bottle for Dravenzo. Line 1: 290 × 25% × $4,380 = $317,550. Fee: $20,758,608 × 3% = $622,758; the difference from the billed amount is $83,034 after rounding.
Fifteen cents of every invoiced dollar is disputable in the example
Harbor Union Q2 2026 Part D invoice: what is owed, and the four causes of variance
Owed, $3,629,168Preferred rate not earned, $470,587Fee above cap, $83,034340B contract pharmacy, $76,320Already paid in Q1, $25,482
$4,284,591 invoiced$3.6M$470.6K
Fictional example from this guide
Show the numbers
Owed, $3,629,168
Preferred rate not earned, $470,587
Fee above cap, $83,034
340B contract pharmacy, $76,320
Already paid in Q1, $25,482
$4,284,591 invoiced
$3.6M
$470.6K
$83K
$76.3K
$25.5K
1,210 of 36,940 prescriptions fail a test, and 632 of them carry most of the money
Prescriptions caught by each claim-level test, same invoice, with the dollars at stake
Formulary test$470,587 off; the claims stay payable at 8%632 prescriptions
340B test$76,320388 prescriptions
Duplicate test$25,482190 prescriptions
Fictional example from this guide · The other 35,730 prescriptions pass all ten checks. The fee is tested at line level.
Show the numbers
Test
Prescriptions
Formulary test
632 prescriptions
340B test
388 prescriptions
Duplicate test
190 prescriptions
Four contract details that change a rebate line's arithmetic
The price date
Is the rate applied to the list price on the fill date, on the first day of the quarter, or at the invoice date? The example's clause 4.1 uses the first day of the quarter. A list price change mid-quarter makes the choice matter, and contracts vary.
Price protection
A rebate that compensates the payer when list price rises above an agreed rate. IQVIA calls it a standard part of rebate work, with "numerous variations that drive different calculations".2 Check it against WAC history, separately from the base rate.
The fee basis
Administrative fees are usually a percentage. Of what, and capped where? The base can be list price, net price or ingredient cost. Fees are also a Best Price question: bona fide service fees are excluded from it by rule, and others may not be.6
Puerto Rico
Contracts differ on whether Puerto Rico prescriptions may be billed, and a local list price can differ from the US list price. IQVIA notes this can also disturb government price calculations and is hard to flag without help from the PBM.2
07 · 340B, Medicaid and duplicates
340B duplicate discounts, Medicaid overlap and prescriptions billed twice
In shortA prescription can be filled once and discounted several times: by the 340B price, by a State Medicaid rebate, by a plan's rebate. Federal law bars one of these pairings, Medicaid and 340B. Your contracts bar the rest. Finding them means testing each row against outside lists on the date of dispensing, with care about what a match proves.
340B purchases: a discount program growing faster than the market
340B purchases reached about $100 billion in 2025
Covered entity outpatient drug purchases, $ billions
66.32023
81.42024
1002025
Source13,33,34 · HRSA's figures, as stated in its August 2026 Federal Register notice; 2025 is approximate. 2024 grew 22.8%. Hospitals were about 87% of purchases in both 2024 and 2025, per Drug Channels Institute and the American Hospital Association's news service.
Show the numbers
Calendar year
$ billions
2023
66.3
2024
81.4
2025
100
340B grew more than four times as fast as manufacturers' net drug sales
Drug Channels Institute also reports a CMS estimate that "10% to 35% of total Part D claims will be subject to 340B pricing".33 Those claims may also appear on a Part D rebate invoice, which is the problem this check addresses.
What the 340B statute bars, and what your contract adds
The statute
A covered entity "shall not request payment" from Medicaid for a drug "subject to the payment of a rebate to the State". This is the duplicate discount ban, in 42 USC 256b(a)(5)(A). The next paragraphs let a manufacturer audit a covered entity's records under procedures the agency sets.9
Your contract
The statute says nothing about commercial or Part D plan rebates. Excluding a 340B prescription from those rebates is a clause. The example's clause 6.3 excludes claims at a contract pharmacy listed in the federal database on the dispensing date, and claims carrying Submission Clarification Code 20.
Why the 340B flag alone misses claims
NCPDP's Submission Clarification Code 20, in field 420-DK, marks a claim as 340B. Some payers require it, New York Medicaid among them, along with a basis of cost of 08 in field 423-DN.35
A contract pharmacy often cannot set it at the counter: HHS's inspector general found administrators deciding 340B eligibility after drugs are dispensed, so the pharmacy did not know at the time, and HRSA's 2026 notice describes eligibility decided "after the fact".36,13
We found no public figure for how many claims lack the flag. So careful teams use two tests: the database match on the date of dispensing, and the flag. IQVIA notes that manufacturers use different internal and external sources and that "Currently available tools only allow a specific source of data to be used for 340B validations".2
About one in five 340B prescriptions in the example carried no flag
78 in 100
contract pharmacy prescriptions on the fictional invoice also carried Code 20: 301 of 388. The other 87 turned up only through the database match.
Fictional example from this guide
Show the numbers
Measure
Value
contract pharmacy prescriptions on the fictional invoice also carried Code 20: 301 of 388. The other 87 turned up only through the database match.
78 of 100
A database match does not prove a 340B fill. A contract pharmacy serves ordinary patients too. Under the replenishment model that HRSA calls the standard approach, a fill is dispensed from regular stock and checked for eligibility later, and the covered entity then restocks at the 340B price.13 Your clause decides what a match means: excluding every claim at a listed contract pharmacy on that date, as the example does, is a contract term that a payer may challenge. Know what yours says before you cite it, and expect the payer to ask.
Duplicates and overlaps: main, adjustment and earlier quarters' files
Repeat billing
Same fill, later quarter
The example's test needs all three keys to match: prescription number, fill date and pharmacy. It finds 190 Q2 claims that repeat Q1 claims, $25,482 under clause 8.2. A weaker key produces false alarms on refills.
Two files
Main and adjustment files overlap
IQVIA calls overlapping data in multiple files the most challenging file scenario, forcing a merged file so that the amount can be reconciled at script level.2 Reversals and rebills add more.
State overlap
A plan's rebate and a State's rebate
Medicaid managed care drugs are eligible for the statutory rebate.10 A plan's supplemental invoice for the same fill needs its contract's answer. State files with claim-level detail make a match possible; summary files do not.
Look-back windows sit here too: clauses cap how many quarters back a claim can be billed. IQVIA notes that the number of back-bill periods varies by contract, which is why one rule cannot cover every payer.2
08 · What goes wrong
Twelve rebate invoice errors, and which check catches each one
In shortErrors cluster in four places: the contract, the formulary position, the claims and the fee arithmetic. Several look right at every level above the prescription. No public dataset says how often each one happens, so rank them on your own paid invoices.
List price changed mid-period; unit mix-ups between cartons and doses
WAC history; dosing check that allows for loading doses
Test first for the errors that repeat and cost the most per claim
Dollars at stake per claim →
Sample it
Test every line
Check occasionally
Automate it
Tier moveExclusivityAmendment340B overlapDuplicatesFee cap
How often it appears →
Illustrative · replace with your own numbers · Positions are our judgment from the example; no public dataset ranks rebate errors. Replace them with your own paid invoices.
Show the numbers
Item
How often it appears (0–1)
Dollars at stake per claim (0–1)
Tier move
0.58
0.72
Exclusivity
0.17
0.66
Amendment
0.25
0.40
340B overlap
0.72
0.58
Duplicates
0.72
0.26
Fee cap
0.14
0.17
Vendor estimates of rebate leakage, and how far to trust them
Leakage is the trade's word for rebate money paid that was never owed.
Published leakage figures range from 2% to 10%, and all come from sellers
Vendors' stated share of rebates at risk, as worded by each. High end of each range shown
'Adjustment in rebate exposure', 3–10%, 2013a software vendor's executive10%
'Noncompliant discounts', 5% of drug discounts, 2023a data company's executive5%
Rebates 'compromised', 2–3%, 2025a coverage data vendor3%
Source37,38,39 · None publishes a dataset. They measure different things and should not be added or averaged.
Show the numbers
Vendor statement
High end
'Adjustment in rebate exposure', 3–10%, 2013
10%
'Noncompliant discounts', 5% of drug discounts, 2023
5%
Rebates 'compromised', 2–3%, 2025
3%
We found no independent audit that measures the share of commercial or Part D rebate dollars paid in error, as of November 2026. A vendor-published figure of 2% to 3% of rebates may be a fair place to start your own test, and it is still a seller's number.37
09 · What it risks
What a wrong rebate payment risks: lost dollars, Best Price, interest and audited accruals
In shortAn error costs money directly, and it can spread. In some channels a rebate can reach Best Price, the figure that sets rebates to every State and 340B prices. Late payment brings fees or interest. The estimate on the books, called the accrual, depends on these numbers, and the people who sign the financial statements answer for them.
Which rebates reach Best Price, channel by channel
Best Price is the lowest price a maker offers an eligible buyer in a quarter, net of rebates and discounts. It matters because the basic Medicaid rebate per unit is the greater of 23.1% of average manufacturer price (AMP), or AMP less Best Price.10,12 A lower Best Price raises the rebate on every Medicaid unit. Best Price also feeds 340B ceiling prices, as CMS notes in explaining why its GENEROUS rebates leave it unchanged.19
Who receives the rebate
Best Price treatment under 42 CFR 447.505
Part D plan, Medicare Advantage drug plan, qualified retiree plan
Excluded: "prices charged which are negotiated by a prescription drug plan under Part D"6
State Medicaid agency
Excluded: national agreement and CMS-authorized supplemental rebates "paid to State Medicaid Agencies"6
PBM
Excluded, with two named exceptions: mail-order pharmacy purchases, and rebates designed to adjust retail or provider prices6
Health plan or HMO, including a managed care organization
Eligible entity: rebates can count. A Medicaid plan's rebate is outside the named State agency exclusion, so have counsel review direct managed Medicaid agreements6
Our summary of the regulation. How a given contract is treated is a question for your government pricing team and counsel. A later payment or credit counts too: Best Price must be adjusted if rebates "subsequently adjust the prices available".6
Once Best Price sets the rebate, each $100 it drops adds $100 per Medicaid unit
Basic Medicaid rebate per unit under the formula, AMP of $3,600, three Best Price levels
Best Price $2,850: 23.1% of AMP is greater23.1% × $3,600 = $831.60$832
Best Price $2,700: AMP less Best Price$3,600 − $2,700$900
Best Price $2,600: AMP less Best Price$3,600 − $2,600$1,000
Illustrative · replace with your own numbers · Illustrative. On 10,000 Medicaid units a quarter, the step from $900 to $1,000 costs $1,000,000. Inflation rebates are left out. No real product's prices are shown.
Show the numbers
Best Price
Basic rebate per unit
Best Price $2,850: 23.1% of AMP is greater
$832
Best Price $2,700: AMP less Best Price
$900
Best Price $2,600: AMP less Best Price
$1,000
Reports and penalties
Price reports are due within 30 days after the quarter, certified by the CEO, CFO or a delegate, and can be revised for 12 quarters. Records stay for 10 years.22 The statute sets penalties of $10,000 a day for late price data and up to $100,000 for each item of knowingly false information.8 Adjusted for inflation, the maximums are now $23,647 and $236,451.40
Interest and fees
On State Medicaid invoices interest runs from day 38 after the postmark, at a rate tied to 13-week Treasury bills.21 On contract invoices the late fee is whatever the contract says, and IQVIA reports windows shortening, with quarterly terms moving to monthly.2
The rebate accrual and the true-up that follows each invoice
Drug makers book sales net of expected rebates. That estimate is the accrual. When the invoice arrives, finance compares it with the estimate and books the difference: a true-up. One drug maker's 2025 annual report warns that "Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation".41
In the example, Northwind Bio accrued $4,092,000 for this quarter. It will pay $3,629,168 and has $655,423 under dispute. Finance has to decide how much of the disputed amount to keep accrued until the payer answers, and it needs the clause, the rows and the decision to support that call.
The accrual sat $192,591 below the invoice and $462,832 above what is being paid
Northwind Bio, Harbor Union Q2 2026, fictional
Invoice as billed$4.3M
Q2 accrual on the books$4.1M
Undisputed payment$3.6M
Fictional example from this guide
Show the numbers
Amount
Dollars
Invoice as billed
$4.3M
Q2 accrual on the books
$4.1M
Undisputed payment
$3.6M
A rebate dispute goes to a partner. Its recipient also decides your drug's formulary position next year. That is why many teams want every dispute to carry its clause and rows from the start: the conversation is about a document, and an item the payer can confirm in minutes costs little goodwill. Release 27's warning applies by analogy: repeat disputes for the same reasons, with no new evidence, damage the process.5
10 · The market
The gross-to-net bubble and the rebate market in numbers, 2010 to 2025
In shortRebates, discounts and fees on brand drugs, the gap people call the gross-to-net bubble, are estimated at $416 billion for 2025. Three PBMs process about 80% of prescriptions. Part D rebates grew about fivefold in a decade. The pressure now runs the other way: list price cuts, uncapped Medicaid rebates, negotiated prices and net price contracts are starting to shrink rebate dollars in parts of the market, while each remaining dollar gets harder to check.
Brand reductions from gross to net reached $416 billion in 2025
Drug Channels Institute estimates
2024$356B
2025$416B
Source3,42 · Separate estimates from two annual posts; the institute has changed its scope over time, so read the gap with care. It describes the 2024 growth as the slowest in at least a decade, and in 2026 says the bubble is 'even deflating in parts of the market'.
Show the numbers
Year
Dollars
2024
$356B
2025
$416B
Three PBMs process about 80 of every 100 prescriptions
80 in 100
equivalent prescription claims in 2025 went through three companies, which also aggregate rebates through their group purchasing organizations
At eight makers in 2025, list prices rose and net prices fell
+3.7%
average list price change at eight manufacturers in 2025, with every one at 4.9% or less.3
Drug Channels Institute, unweighted
−1.8%
average net price change at the same eight. Net prices fell at seven of them.3
Drug Channels Institute, unweighted
−51.7%
average discount from list at the three makers that disclosed one.3
Drug Channels Institute, unweighted
Part D offers a further pressure. Milliman's 2023 primer noted that average rebates run "close to 30% of the drug's cost", varying widely by brand, and that the 2025 redesign raises plan liability in ways that can change what plans ask of makers.1 Negotiated prices take effect on ten drugs in 2026 and 15 more in 2027, and a third cycle follows in 2028.11
List price cuts on highly rebated drugs, driven in part by the end of the Medicaid rebate cap, shrink some rebate pools.42 Each of these adds a new kind of line, date or exception, so the checking gets harder even if the total shrinks.
No public figure exists for how many rebate invoices the industry processes, how many prescriptions they carry or how many analysts do the work. One vendor says manufacturers often hold "tens to hundreds of contracts".31
11 · Automation and AI
AI and rebate validation: what software can check, what stays a judgment, and how to measure it
Status as of November 2026
In shortSoftware has automated claim checks at the prescription level for over a decade.38 Newer tools add reading: odd file layouts, contract clauses and formulary files. No regulator has issued a rule on AI in rebate validation that we could find. The test that matters is financial control: can a person see the clause and the row behind every number, and how often does the tool miss what you planted?
Software can take most of the file work; the decisions stay with people
Share of each task we would expect software to do, with a person checking
Software does itPerson decides
Mapping a new file layout85%15%
Finding terms in force80%20%
Position test by plan and month90%10%
340B and duplicate matching85%15%
Recalculating every line95%
Deciding a dispute10%90%
Answering a payer20%80%
Illustrative · replace with your own numbers · Our judgment. Measure your own in a pilot.
Show the numbers
Software does it
Person decides
Mapping a new file layout
85%
15%
Finding terms in force
80%
20%
Position test by plan and month
90%
10%
340B and duplicate matching
85%
15%
Recalculating every line
95%
5%
Deciding a dispute
10%
90%
Answering a payer
20%
80%
Reading has known risks. A contract clause read wrongly produces a confident wrong rate on every line of every invoice. Ask for each term to link to its clause, and have contract operations confirm a new or changed term before it is used.
Which controls apply. FDA's draft guidance on AI sits outside this work, as section 03 explains.27 Use your AI policy, your vendor risk process and your financial reporting controls.26
Testing a tool: plant errors in past rebate invoices and count
Accuracy has two parts. Recalculation asks whether the owed amount is right on a clean line; a random sample of lines measures it. Catching asks whether the tool finds a problem you know is there. Formulary failures and exclusivity failures can be rare, so plant them in copies of past invoices. A small test proves less than it seems to.
Twenty planted tier moves, none missed, still allows a 14% miss rate
95% upper bound on the miss rate when no planted error of one kind is missed
20 plants of one kind, none missed13.9%
40 plants of one kind, none missed7.2%
60 plants of one kind, none missed4.9%
Illustrative · replace with your own numbers · Binomial arithmetic: 1 − 0.05^(1/n).
Show the numbers
Test size
Miss rate could still be up to
20 plants of one kind, none missed
13.9%
40 plants of one kind, none missed
7.2%
60 plants of one kind, none missed
4.9%
Keep clean copies as well and count false alarms on them, because a tool that flags everything catches every plant. Every false dispute also costs time with a payer. We found no published independent test of any rebate validation vendor's accuracy, as of November 2026.
Judgments a rebate lead keeps
What an ambiguous clause means, and whether to raise it now or at renewal.
Whether a contract pharmacy match is enough to dispute under your terms.
Which disputes are worth the conversation, given what else you are negotiating with that payer.
Whether a payment should wait for government pricing, and how to book what is disputed.
The signature on the payment, and on the price report that follows it.22
12 · How rebate teams work today
How rebate operations teams validate today: who does what, and where 19 days can go
In shortAnalysts load files, find terms, run checks and build the case. A lead decides and signs. Contract operations owns the terms, accounting the accrual, government pricing the price effect. Under a shortening payment window, a team may pay in full to avoid a late fee, and chase the money later.
Analyst to controller: who handles a rebate invoice
RA
Rebate operations analyst
Loads files, maps new layouts, runs the scrubber, works out what failed and prepares the dispute list.
Cares about: reaching the due date with the checks done.
RL
Rebate operations lead
Decides each exception, signs letters and payments, and answers payers.
Cares about: evidence that lets a decision take a minute.
CO
Contract operations
Keeps the agreements, amendments and schedules, and interprets clauses with legal.
Cares about: the amendment in force that quarter.
GA
Gross-to-net accounting
Books the accrual, the true-up and the dispute reserve; a controller adds a second signature on large payments.
Cares about: numbers that can be traced at audit.
GP
Government pricing
Reports Best Price and average manufacturer price, and reviews payments that could affect them.
Checking plans, position and overlaps takes nearly half of an invoice's days
Days from receipt to decision for one quarterly payer invoice, by hand
Files and terms in forcePlans, groups and positionDuplicates, 340B, MedicaidRecalculating and decidingLetter, packet, signatures
By hand, 19 days55432
Illustrative · replace with your own numbers · An estimate. No public source measures days per invoice; time three of your own.
Show the numbers
Files and terms in force
Plans, groups and position
Duplicates, 340B, Medicaid
Recalculating and deciding
Letter, packet, signatures
By hand, 19 days
5
5
4
3
2
Contract windows differ, and no public benchmark exists for them. IQVIA's consultants report that "several quarterly payment terms" have recently become monthly, which leaves less time for the same checking.2 Under that pressure a team may pay on time and pursue the money afterward, which then depends on the payer's willingness to reopen a closed quarter and on systems that can reprocess a part of a paid claim file.2
Spreadsheets, a script scrubber or an outside team
In house
Spreadsheets and macros
Flexible and cheap to start. The weak points are file size, formulas that drift between analysts, and little record of why a line was disputed.
Software
Revenue management plus a scrubber
The established route. Rule-based, and strong on standard checks. The gaps IQVIA names are new layouts, plan and product pairs, 340B sources and reprocessing part of a paid file.2
Outsourced
An outside contract operations team
A provider loads files and runs checks on your behalf. It moves the hours elsewhere, and your team still interprets clauses, decides disputes and signs.
Part B · See it working
Botminds Rebate Claims Validation on a $158.7 million quarter of payer invoices
Part A described the work without naming a product. This part shows how Botminds does it, at a fictional biotech, Northwind Bio, with ten payer invoices in the second quarter of 2026. Every company, person, drug, contract clause and number in the screens is sample data, and the clauses are sample text written for the example.
13 · One invoice, start to finish
Harbor Union's $4.28 million Part D invoice: reconciled, disputed with four clauses, signed and scheduled
In shortThis is the example from the top of the page, inside the product. Agents read the invoice, the contract and the plan's formulary file, and recalculate all 13 lines minutes after arrival. Priya Ranvelle, the rebate operations lead, decides four exceptions with each clause and row in front of her, sends one letter, signs, and the undisputed $3,629,168 is scheduled a day before it is due.
1
Ten invoices on one strip, one just arrived
Wednesday, October 7, 2026. Priya's reconciliation screen shows all ten second-quarter invoices with status and due date: Brackenfield waits for her signature, Crestline has six exceptions to decide, Northgate's dispute has gone out, Pinecrest is still being checked.
Harbor Union arrived at 7:12 a.m.: 36,940 claims and $4,284,591 under contract HUR-2025-022, due November 6. The lines are listed and the checks have not yet run. She presses Reconcile.
The quarter and the new invoice. Every payer invoice with its status, and the invoice lines before the check.
2
Every line beside its term, its position and its claims
The invoice and file intake ties 36,940 claims in two files to the invoice total. The contract term reader returns seven terms in force. The eligibility and formulary checker reads Harbor Union's second-quarter file and the position grid fills, month by month. The other two checkers work through the claims.
Owed under the contract: $3,629,168. Variance: $655,423. Four lines are red and six more have claims excluded. The screen says reconciled four minutes after arrival.
Invoice lines against the contract. Billed, then checked, then owed and variance. On the right, the position each plan held over four quarters: three plans turn red for April, May and June.
3
Line 3: billed at 25%, owed at 8%
Priya opens line 3. The invoice bills 276 cartons at 25% of the list price. Sample clause 4.2(b) is highlighted: on Tier 4, or with step therapy at any time in the quarter, the rate is 8%.
Below it, the row from Harbor Union's own file: effective April 1, 2026, plan S7742-004, Tier 4, non-preferred, step therapy. Owed: $96,710. Lines 4 and 6 fail for the same reason.
One line, all its evidence. The invoice row, the sample clause, the position and the payer's formulary row in one column.
4
Four exceptions, each with its clause, rows and a recommendation
The invoice opens on its exceptions, grouped by cause. The first is 632 claims and $470,587, marked 98% sure. The calculation is on screen: 632 cartons × 17% of the $4,380 list price, with the three lines behind it and the clause highlighted beside them. The recommendation reads "dispute in full".
Priya disputes it, then applies the recommendations on the other three in her own name: the 340B claims, the claims already paid in the first quarter, and the fee above its cap.
Exceptions to decide. The reason, the calculation, the lines and the recommendation, with the sample contract on the right.
5
One letter, one signed packet, payment before the due date
The dispute letter writer turns her four decisions into one letter to Harbor Union's rebate services team, with $655,423 disputed, each item with its clause, claim count and amount, and a claim list attached. Only decided items go in, and Priya sends it through the payer's portal.
The packet shows $4,284,591 invoiced, $655,423 disputed, $3,629,168 to pay and the true-up of $462,832 against the $4,092,000 accrual. She signs. The invoice is under the $25 million line where a controller signs as well, and Part D rebates are recorded as excluded from Best Price. Payment is scheduled for November 5.
The dispute letter. One letter, every decided item with its clause, its claims and its amount.
The solution's design target is a 4.2-day median from invoice received to decision, against an estimated 19 days by hand. It is a target, to be measured on your own invoices.
14 · Every screen
The rest of the rebate cycle, from a fee above its cap to the quarter's dashboard
In shortOne invoice is the story. These screens show the rest: other kinds of exception, the signature with its meaning, the record that stays behind, every invoice and contract term, what the quarter found, and the settings that belong to you.
Fee, 340B, repeat-claim, exclusivity and prior authorization exceptions across the sample invoices
The payer's formulary file. The rows behind the exception, with a note that the data is used under the data agreement.
A fee above its cap. Line 13: 3.4% billed on $20,758,608 of list price against a 3% cap, $83,034 over.
Contract pharmacy claims. 388 claims, 301 of them also flagged with Code 20, excluded under the sample clause.
Claims already paid in Q1. 190 claims matched on all three keys, with the earlier file's rows beside the reason.
An exclusivity rebate that failed. On Crestline's commercial invoice, a competing brand joined the tier on June 12, so June's $1,429,632 exclusivity line falls away.
Prior authorization, two months. A commercial plan added prior authorization in April and May. Those lines fall to the 18% rate.
Applying dispute recommendations, signing the payment and the record that remains
Apply the recommendations. Decisions applied in bulk still carry the decider's name.
Sign with meaning. The signature, what it means and the time stay with the packet.
The payment packet. What is in it, the amount to pay and the true-up against the accrual.
Signature and Best Price record. Part D rebates are recorded as excluded, and government pricing is informed.
A controller's second signature. Brackenfield's $27.1 million payment routes to the controller as well.
The activity record. Every agent step and every human decision, with who and when, in a record that cannot be edited.
A payer's reply, matched. Northgate accepts one item and questions the other. Each goes to its own next step.
Every payer invoice, contract term and setting across the quarter
All invoices. Every payer by channel, with claims, invoiced and disputable amounts, stage and due date.
Contract terms. Each term the agents check, linked to its clause and amendment. The clause text is sample text written for this example.
What the quarter found. Sample data: disputable dollars found and recovered, by cause and by channel.
Where leakage sits. Payer against cause, a starting point for the next contract conversation.
Checks on each line. Ten checks, each one yours to switch.
People and data sources. Who decides what, and where invoices and data arrive.
Thresholds and signers. The controller's line, the government pricing review line, the smallest exception a person decides, and who signs letters.
Select any screen to open it larger. The biotech, payers, drugs, people and figures are fictional.
What the sample quarter found, by cause
Formulary placement is the largest cause in the sample quarter, at $2.5 million
Disputable dollars found on ten fictional Q2 2026 invoices, $158.7 million invoiced
Formulary placement$2.5M
340B overlap$1.9M
Plan eligibility$1.3M
Duplicate claim$1.2M
Look-back window$760K
Medicaid overlap$390K
Territory$140K
Quantity$80K
Rate and fees$60K
Fictional example from this guide · $8.3 million in all, 5.2% of invoiced in the sample. The design target is 4.6% of invoiced over a year, against 1.6% by hand in the sample's earlier year. Disputable is more than recoverable: $1.2 million had been recovered at the sample's date, with replies still due.
Show the numbers
Cause
Disputable found
Formulary placement
$2.5M
340B overlap
$1.9M
Plan eligibility
$1.3M
Duplicate claim
$1.2M
Look-back window
$760K
Medicaid overlap
$390K
Territory
$140K
Quantity
$80K
Rate and fees
$60K
15 · Agents, and who signs
Seven rebate agents recommend; the rebate lead decides, and large payments take a second signature
In shortEach agent has one job and limits it does not cross. None of them refuses a payment, sends a letter or releases money. The rebate lead decides each exception, or an analyst under $250,000. The controller adds a signature above $25 million, and government pricing reviews payments that could set a new Best Price.
From invoice intake to the payment packet: seven agents and their limits
Invoice and file intake
Reads payer invoices and utilization files in any layout, maps them to the rebate standard, merges main and adjustment files and ties the claims to the invoice total.
Never changes a payer's data. It stops and asks when totals do not tie.
Contract term reader
Reads each agreement and every amendment and keeps the terms in force: rates, tier conditions, exclusions, fees, look-back and schedules, each linked to its clause.
Never uses a new or changed term before contract operations confirms it.
Eligibility and formulary checker
Checks products, dates, plans, groups, territories and look-back, and the formulary position month by month against the tier conditions in the contract.
Never refuses a payment. It groups exceptions by cause and recommends.
Duplicate and overlap finder
Finds claims billed twice across files and quarters, 340B contract pharmacy claims and claims also on a State Medicaid invoice.
Never calls a duplicate unless prescription number, fill date and pharmacy all match.
Rate and quantity checker
Recalculates the rebate for every claim with the rate grid and list price history, checks fees and price protection, and compares quantities with label dosing.
Never recommends a partial payment without saying what is paid and what is disputed.
Dispute letter writer
Turns the rebate lead's decisions into one letter that cites the clause and attaches the claim list for each item.
Never includes an undecided item, and never sends. A person sends the letter.
Payment packet assembler
Builds the packet, routes it for e-signature by amount, runs the Best Price check against your thresholds, schedules the payment in the ERP (your finance system) and posts the true-up.
Never releases a payment without the required signatures. Those that could set a new Best Price wait for government pricing.
Who decides each exception, signs each payment and reviews Best Price
Decides and signsRebate operations leadDisputes, part-pays or accepts each exception; sends the letter; signs "I prepared and approve this payment".
Decides under $250,000Rebate operations analystWorks the quarter's invoices from one list by stage and due date.
Second signatureController, gross-to-net accountingCo-signs payments above $25 million, seeing each exception, its clause and the true-up.
Owns the termsContract operationsConfirms each new or changed term before it is used on an invoice.
Reviews the price effectGovernment pricingReviews payments whose rebate after disputes is above 36% of list price, or that could set a new Best Price. Part D payments are recorded for review.
The thresholds are the sample's settings, yours to change. Which rebates reach Best Price is a legal question that the regulation answers by channel (section 09), so your government pricing team and counsel should set the routing, especially for direct managed Medicaid agreements. The agents and signatures support your financial reporting controls; they do not replace them.
The rebate lead, analyst, controller and pricing reviewer in the screens
Fictional, from the sample data
PR
Priya Ranvelle · rebate operations lead
Decides exceptions, sends dispute letters and signs payments.
"Show me the line, the clause and the formulary row, and I can decide in a minute."
SP
Sam Patel · rebate operations analyst
Works the quarter's invoices before their due dates.
"Four hundred thousand claims in a spreadsheet is no check at all."
DO
Dana Okafor · contract operations
Confirms terms and amendments.
"The rate is only right if the amendment in force that quarter is the one we read."
OH
Omar Haddad · controller, gross-to-net accounting
Second signature above $25 million; accrual true-ups.
"I sign what I can trace."
LO
Lena Ortiz · government pricing
Reviews payments that could set a new Best Price.
"Tell me which channel it is before you tell me the number."
16 · What goes in and out
Payer invoices, contracts and formulary files in; line-by-line reconciliation, cited letters and signed packets out
In shortThe solution reads the files a rebate cycle already runs on and leaves behind a line-by-line reconciliation, exceptions with their clauses and rows, letters, signed packets and true-ups. Your revenue management system and ERP remain the systems of record, and each check and threshold is a setting with a record of who changed it.
From payers
Rebate invoices and utilization files, in the rebate standard or the payer's own layout
Formulary files, month by month
Replies to disputes
From your company and public sources
Rebate agreements, amendments and schedules
List price history
The federal 340B database
State Medicaid invoices
Your thresholds and signers
Agents read, match and recalculateEvery line and every claim, against the contract in force and the position held
Dispute letters citing each clause, with claim lists
Signed payment packets
Accrual true-ups and Best Price records
Dashboards by cause, channel and payer
What changes for the team
Exceptions to decide, already written up
A formulary test on every line
A record behind every payment
Where a rebate invoice's days go, by hand and at the design target
The design target cuts receipt-to-decision from an estimated 19 days to 4.2
Days for one quarterly payer invoice, estimated by hand and at the solution's target
By hand (estimate)With the solution (design target)
Collecting the invoice and mapping files3 days0.2 days
Finding the terms in force2 days0.1 days
Plans, groups and formulary position5 days0.4 days
Duplicates, 340B and Medicaid overlap4 days0.3 days
Recalculating and deciding3 days1.8 days
Letter, packet and signatures2 days1.4 days
Illustrative · replace with your own numbers · The solution's own estimates and design target, for you to measure. The last two rows stay longest because people decide and sign there.
Show the numbers
By hand (estimate)
With the solution (design target)
Collecting the invoice and mapping files
3 days
0.2 days
Finding the terms in force
2 days
0.1 days
Plans, groups and formulary position
5 days
0.4 days
Duplicates, 340B and Medicaid overlap
4 days
0.3 days
Recalculating and deciding
3 days
1.8 days
Letter, packet and signatures
2 days
1.4 days
Systems a rebate validation rollout connects to
Payer rebate portalsInvoices and files in; letters out
Secure file transfer and mailboxUtilization and formulary files
Revenue managementContracts, rates, accruals
Contract repositoryAgreements and amendments
ERPPayments and true-ups
Government pricing systemBest Price review and records
Federal 340B databaseCovered entities, contract pharmacies
Identity and accessRoles, signing limits, separation of duties
For each, check whether it has an API, a file feed, or only screens, and who owns it. Payer data is used only under its data agreement.
Your contracts, revenue system and dispute process stay
Your rebate agreements
Read as they are. Each term keeps a link to its clause, and contract operations confirms it.
Your revenue management system
It stays the system of record for contracts and accruals. Reconciled results and true-ups go to it.
Your script scrubber
It can stay. Its results can be one more input, and the formulary and clause checks sit beside it.
Your payer relationships
A person sends every letter. Items carry clauses and rows a payer can confirm quickly.
Your government pricing process
Your team sets the routing and reviews what it needs to review, with a record of each check.
Your controls and audits
Role-based access, maker-checker (one person prepares, another approves), e-signature and an activity record built for internal audit to test.
The design commitments behind each rebate payment
1
Position tested on every line
The design target is 100% of invoice lines tested against the position held, month by month.
2
Every dispute carries its clause
Reason, clause, rows and calculation travel from the exception into the letter.
3
Agents recommend; people sign
A named person decides, sends and signs, and the record shows who did what and when.
Part C · Are you ready to automate?
Automated rebate invoice validation: what it costs, what it returns and how to test it
You pay rebate invoices, or lead the people who do, or answer for the numbers they produce. This part is written for you: what leakage and late payment cost today, what automating the checks could return, whether your team is ready, and what to ask any vendor of rebate validation, including us.
17 · What leakage and delay cost
What unvalidated rebate invoices cost you in overpayments, late fees and rework
In shortStart from your own paid invoices. No regulator or independent study publishes how much rebate money is paid in error, so vendor figures are the only public estimates, and they measure different things. A few published facts frame the stakes: the size of the flow, the interest clock on State invoices and the penalties on price reports.
2–3%
of rebates "compromised" by leakage at a mid-size maker, by one vendor's research. Another seller said 3% to 10% of rebate exposure in 2013. Neither publishes a dataset.37,38
MMIT, February 2025 · Pharmaceutical Commerce, 2013
37 days
to pay a State Medicaid invoice before interest begins to run. Commercial and Part D windows are in each contract, and consultants see them shortening.21,2
CMS, updated June 2026 · IQVIA, 2023
$236K
the maximum civil money penalty for each item of knowingly false price information, and $23,647 a day for late data. The statute's $100,000 and $10,000, adjusted for inflation.8,40
42 USC 1396r-8(b)(3)(C) · 45 CFR 102.3
On $600 million a year, each point of leakage is $6 million
Dollars at stake a year if a given share of invoiced rebates is disputable and goes unfound
1% of invoiced$6M
3% of invoiced$18M
5% of invoiced$30M
Illustrative · replace with your own numbers · $600 million is an assumption; use your own rebate spend. Disputable is more than recoverable: payers can and do push back.
Show the numbers
Unfound share
Dollars a year
1% of invoiced
$6M
3% of invoiced
$18M
5% of invoiced
$30M
What nobody publishes. There is no public figure for the share of rebate dollars paid in error by channel, hours per invoice, the share of disputes payers accept, typical contract payment terms or the size of late fees. Vendor figures for some of these come without a dataset. Measure your own.
Re-checking one paid quarter to find your own leakage
Cost
Where it hides
How to find your number in a week
Position failures
Lines paid at the preferred rate after a tier move
Take your three largest rate-tiered contracts and test last quarter's lines against the payer's formulary files by month
Claim overlaps
340B, State Medicaid and repeat claims inside large files
Run one paid file against the federal 340B database by dispensing date, and against the prior quarter on three keys
Analyst time
Mapping layouts, finding amendments, building dispute lists
Time three invoices, large and small, with a stopwatch per step
Late fees and interest
Accounts payable, booked as a cost of doing business
Pull a year of fees and interest paid, by payer
Paying first, chasing later
Credits that arrive quarters later, or never
Disputed dollars from last year, and how many came back
Accrual surprises
True-ups that move a quarter's net sales
The last eight quarters' true-ups, by channel
Best Price restatements, weaker renewals and audit hours
The Best Price restatementA rebate that reaches Best Price changes the rebate to every State, and can reopen earlier quarters for up to 12 quarters.22
The renewal you negotiate blindWithout position data by plan and month, you cannot see which plans gave what you paid for.
Time with auditorsHours spent rebuilding why a payment was made, long after the analyst has moved on.
The dispute that came too lateSome contracts close the window. Evidence gathered after payment often buys less than evidence sent before.
Your analysts' judgmentSpent on mapping files instead of reading clauses and talking to payers.
18 · Your return
What rebate validation returns when you count recovered dollars against hours and cost
In shortPut in your own numbers. The calculator separates what is found from what comes back, because only the second is money. Nearly every default is an assumption to replace, including the share of disputes payers accept, and that input decides the answer more than any other.
Position, overlaps, fees, time: where a rebate team gains
Disputable dollars
Every line position-tested
Lines that pass a rate check are tested against the plan's position that month.
invoiced × added share found × share recovered
Claim overlaps
Every prescription checked
340B, State Medicaid, duplicates and look-back are tested on all rows, instead of a sample.
excluded claims × rebate per claim
Fees
Fee base and cap recalculated
Small rates on large bases add up, and they are easy to confirm.
fee base × (rate billed − cap)
Analyst time
Exceptions to decide
Files are mapped and lines checked before a person opens the invoice.
invoices × hours saved × hourly cost
On-time payment
Decisions inside the window
Fewer late fees, and less need to pay first and chase later.
fees and interest paid last year, before and after
Accruals
Narrower true-ups
Position changes reach accounting while the quarter's estimate can still use them.
size of the last eight true-ups, before and after
Invoiced dollars, disputable share and the share payers accept
The starting and target percentages come from the solution's sample and design target, and describe no real company. Every input marked illustrative is an assumption.
Your invoicesShare found and recoveredHours and cost
Illustrative yearly value
Added disputable dollars found$0
Of those, dollars that come back$0
Analyst time released, valued$0
After your yearly cost$0
Share of added disputes needed to break even0%
Formulas, per year: Added disputable = invoiced × (share with validation − share today) Dollars back = added disputable × share that comes back Time released = invoices × (hours today − hours after) × hourly cost After your cost = dollars back + time released − yearly cost Break-even share = (yearly cost − time released) ÷ added disputable; 100% means added disputes alone cannot cover the cost
Not counted: late fees avoided, Best Price effects, narrower true-ups, audit hours and goodwill. Released hours are value only when you decide what they are for. A dollar that comes back as a credit next year is worth less than one never paid.
What payers accept decides the return, more than hours saved
Yearly value after cost on the calculator's defaults, at three acceptance rates
15% of added disputes come back$2.5M
25% come back$4.3M
40% come back$7M
Illustrative · replace with your own numbers · $18,000,000 of added disputable dollars, $306,000 of analyst time, $500,000 of yearly cost. Replace all of them.
Show the numbers
Acceptance rate
Value after cost
15% of added disputes come back
$2.5M
25% come back
$4.3M
40% come back
$7M
A team whose payers rarely reopen paid quarters and whose contracts carry few position conditions will see much smaller numbers, and should say so before buying anything. A team with many tiered contracts and a heavy Part D or commercial mix has more to test.
Start here19 · Readiness check
How ready your rebate operations team is: contracts, formulary files, disputes and sign-off
In shortPick the answer closest to your team today. Eight questions score 0 to 2; the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.
1
Invoices and rebate dollars
How many payer invoices do you handle a year, and how much do they bill?
Why it mattersVolume and dollars turn small percentages into a business case. A few small contracts rarely justify new software.
A strong answer"About 40 invoices a year across four channels, over $600 million billed."
2
Position-tiered contracts
How many of your rebate rates depend on formulary position, restrictions or competitors on the tier?
Why it mattersPosition conditions are where a rate check passes and the plan still earned less. GAO found them at every Part D sponsor and maker it reviewed.7
A strong answer"Most brand rates, usually with a quarter-long test and a lower rate otherwise."
3
Formulary evidence
Do you receive the formulary files your clauses depend on, month by month?
Why it mattersA position test needs evidence you can cite. Contract rights to the file, or a licensed coverage data source, come first.
A strong answer"The contracts require monthly files, and we receive them from most payers."
4
Contracts in one place
Can you find every agreement, amendment and schedule in force for a given quarter, today?
Why it mattersSoftware can read clauses and link terms to them, provided the documents exist in one place and someone owns the terms.
A strong answer"Contract operations keeps a repository, and every amendment carries an effective date."
5
Your baseline
Do you know your disputable share, your acceptance rate, your days from receipt to decision and your late fees?
Why it mattersNo public benchmark exists for any of them, so your own baseline is the only way to prove an improvement.
A strong answer"1.8% disputed last year, 40% accepted, 17 days to decide, $90,000 in late fees."
6
Files and systems
Can software reach your payer files, and can results reach revenue management and the ERP?
Why it mattersPortals with no export and manual uploads work, but they add set-up, and they decide how much of the cycle runs unattended.
A strong answer"Secure transfer from most payers, and the ERP takes a payment file."
7
Owner and budget
Is there a named owner of rebate validation with a budget to change how it is done?
Why it mattersThis work crosses market access, contracts, finance, government pricing and IT. Without one owner it stalls.
A strong answer"The head of contract operations sponsors it, and finance has seen the leakage estimate."
8
Controls and data rights
Do you have a path to approve AI over claim data: payer data agreements, privacy review, financial controls and human sign-off?
Why it mattersPayer files come under data agreements, and rows may carry identifiers.25 Payments sit inside your financial reporting controls.26
A strong answer"Legal, privacy and internal audit have a path, and every payment needs a named signer."
9
The evidence behind a payment · for reflection
If your controller picked one line from last quarter's largest payment tomorrow, what would have to be true for you to show the clause, the formulary row and the decision in under a minute?
Why it mattersYour answer lists the gaps. Each gap is a candidate job for software: reading, matching, recalculating or writing up.
A strong answerA short, specific list, for example: "every term linked to its clause, every plan's position by month, every decision with a name and a reason."
A low score means securing formulary files and contracts first
0–6
Explore
Build the baseline first: re-check one paid quarter on your three largest tiered contracts, bring contracts into one place, ask payers for formulary files, and name an owner. Start narrow with one channel.
7–11
Ready to pilot
Run a measured pilot on 8 to 12 of your own paid invoices, with errors planted in copies. Compare catches, false alarms and analyst hours with your current process, and keep your people deciding every exception.
12–16
Ready to implement
Plan every channel: contracts and thresholds as settings, signers and limits, portal and ERP links, government pricing review, accounting's true-ups and the record an auditor will ask for.
20 · Questions for any vendor
What to ask a script-level validation vendor about formulary tests, 340B matching and evidence
In shortAsk every vendor the same questions, us included. The answers show how the checks run: what the tool reads, how it tests position, what it calls a match, what evidence you keep and how you would measure it on your own invoices.
Ask
A good answer
A warning sign
Files and contracts
What happens when a payer sends a new layout or changes one with no notice?
Maps it, shows the mapping, stops if totals do not tie, keeps the mapping for next time
A services ticket and a two-week wait
How are main and adjustment files merged, and how do you handle reversals?
Merged at prescription level, with the amount reconciled to the invoice
Each file processed on its own
Who confirms a term read from a contract, and can I open the clause from any number?
Contract operations confirms; each term links to clause and amendment
Terms keyed once into a table with no link
Is plan and product tested as a pair against the contract, on the date?
Yes, in one test
Plan and product each checked against master data
Formulary position
How do you test position? By plan, by month, with restrictions and competitors?
By plan benefit package and month, testing your clause's own time test
A quarterly yes or no at parent plan level
Where does position evidence come from, and can I attach the row to a dispute?
The payer's own file or your licensed source, and the exact row attached
A coverage score with no row
What happens when a change takes effect mid-quarter, after we paid?
Re-runs the subset of claims and shows the new variance
Manual rework outside the system
Overlaps and matches
What counts as a 340B match, and on what date?
Database on the dispensing date, plus the claim's flag, and your clause decides what it means
"340B identified" with no definition
How many keys make a duplicate, and how far back do you look?
Configurable keys; prescription number, fill date and pharmacy at least; several quarters
Refills flagged as duplicates
How do you match Medicaid overlap if a State gives only summary data?
States what it cannot prove, and says so on the exception
Estimates presented as matches
Decisions and evidence
Who decides a dispute, and what is recorded?
A named person, with reason and time; the tool recommends
Disputes sent automatically
How does a payment reach Best Price review?
Checks by channel and threshold, routes to your government pricing team, keeps the record
"That is a separate system" with no link
Can an auditor follow one payment from the invoice to the clause and row?
Yes, with a record that cannot be edited
Evidence exported on request, by hand
Your data and AI
Which AI models do you use, where do they run, and does our data train them?
Named models, a region you choose, no training on your data, in writing
"Proprietary AI", no more detail
How do you handle payers' data agreements and identifiers in claim rows?
Use tied to each agreement; access by role; a documented privacy position
Payer files pooled across customers
Proof
Can we test on our paid invoices, with errors we plant, before we sign?
Yes, blind, with clean copies to count false alarms
Sample data only
What will you report from the test?
Catch rate by error type with the number planted; false alarms; analyst hours; dollars found by cause
One percentage of "savings"
How did you arrive at the leakage figure in your materials?
A clear base, a dataset and a date
"Industry research"
With no published independent test to lean on (section 11), a planted-error test on your own paid invoices is the fairest comparison, and the same test measures your current process.
21 · How to start
Pilot rebate validation on invoices you already paid, then decide on three numbers
In shortMeasure first, then test on your own paid invoices with errors you planted, then run a live quarter in parallel, then decide with three numbers. None of these steps commits you to a vendor.
Time three invoices, one large commercial, one Part D, one Medicaid. That is your baseline.
Pull last year's evidence: disputes filed and accepted, late fees and interest, true-ups, and audit comments on rebates.
Gather 10 paid invoices with their contracts and formulary files, and approval to share them under your payers' data agreements. Copy them and plant known errors.
Run in parallel on a live quarter with your people deciding and signing, and your normal process still paying.
Decide with three numbers: catch rate by error type, false alarms on clean copies, and hours from receipt to decision.
A 14-week pilot ends with a decision on three numbers
Your teamVendor
Time three invoices; pull dispute and fee history
Clear payer data agreements and privacy review
Choose 10 invoices; plant errors in copies
Load contracts, terms and thresholds
Reconcile the test set blind
Parallel run on a live quarter
Score catches, false alarms, hours
Decide
Week 0481214
Illustrative · replace with your own numbers
Show the numbers
Activity
From
To
Time three invoices; pull dispute and fee history
0
2
Clear payer data agreements and privacy review
0
4
Choose 10 invoices; plant errors in copies
2
5
Load contracts, terms and thresholds
3
6
Reconcile the test set blind
5
7
Parallel run on a live quarter
7
12
Score catches, false alarms, hours
11
13
Decide
13
14
Catch rate, false alarms and dollars accepted per payer
Measure
How
Why
Catch rate by error type
Planted errors caught ÷ planted, per type, with the number planted
One percentage hides the tier moves
False alarms
Exceptions on clean copies, in reviewer minutes
Each false dispute costs time with a payer
Recalculation accuracy
300 random lines and fee amounts checked by hand
If none of 300 is wrong, the true error rate is very likely under 1%
Receipt to decision
Days, from invoice in to last exception decided
The window is the constraint
Dollars accepted
Disputed dollars the payer confirms, by cause, over two quarters
Found dollars are claims; accepted dollars are money
The full working-session questions: 15 questions in five groups
Bring rebate operations, contract operations, accounting, government pricing, legal and IT into one room. Each question says why it matters, what a strong answer looks like, and the warning sign.
A
Invoices by channel, payer and due date
A1
How many invoices do we handle by channel, and how large are they?
Why it mattersSets scope and the first channel.
Strong answer · warning sign
Counts and dollars by channel and payer.
One total, nobody sure of the mix.
A2
Which invoices would we keep on the current process, and why?
Why it mattersSmall flat-rate contracts gain little; say so early.
Strong answer · warning sign
A clear exclusion list.
"Everything, day one."
A3
What is our payment window by payer, and what does a late payment cost?
Why it mattersThe window sets the turnaround the work must meet.2
Strong answer · warning sign
A table by contract.
"Finance would know."
B
Clauses, amendments and retroactive changes
B1
Who owns the terms in force, and how fast does a signed amendment reach the checks?
Why it mattersA stale term pays the wrong rate on every line.
Strong answer · warning sign
A named owner, days.
"When someone remembers."
B2
Which clauses test position, and what time test does each use?
Why it mattersThese become the rules.
Strong answer · warning sign
A list, reviewed by legal.
"They're all about the same."
B3
What do we do when a retroactive amendment changes a paid quarter?
Do our contracts give us the right to formulary files, and do we use it?
Why it mattersWithout evidence, a position dispute is an opinion.
Strong answer · warning sign
In most contracts, and files on hand.
Never asked.
C2
What does a 340B match mean under each contract?
Why it mattersA pharmacy on a list is different from a proven 340B fill.
Strong answer · warning sign
Clause by clause, agreed with legal.
One rule for all payers.
C3
Which States send claim-level data?
Why it mattersSummary data cannot prove a Medicaid overlap.
Strong answer · warning sign
A list by State.
Assumed to be all.
D
Decision limits, Best Price review and accruals
D1
Who decides an exception, and at what amount does a second signature start?
Why it mattersSigning limits become settings.
Strong answer · warning sign
Written limits by role.
"It depends who's in."
D2
Which of our rebates reach Best Price, by channel and contract?
Why it mattersThe regulation treats plans and PBMs differently.6
Strong answer · warning sign
A reviewed table.
"Government pricing handles it."
D3
How do we book a disputed amount until the payer answers?
Why it mattersAccounting needs the evidence, and auditors will ask.
Strong answer · warning sign
A written policy.
Case by case.
E
Payer conversations, sponsors and every clause cited
E1
How do payers respond to disputes now, and which ones accept evidence quickly?
Why it mattersAcceptance sets the return.
Strong answer · warning sign
Rates by payer.
"They all push back."
E2
Who sponsors the change, and what budget can move?
Why it mattersA pilot without a sponsor ends as a demonstration.
Strong answer · warning sign
A named executive.
No sponsor.
E3
Which steps would we never let software do without a person?
Why it mattersTells you where the signatures belong.
Strong answer · warning sign
Disputes, letters to payers, payments, thresholds.
"All of it": then start with file mapping and overlap matching.
22 · Questions people ask
Rebate claims validation questions answered: Part D, 340B, Best Price and dispute timing
In shortThe questions rebate teams and buyers search for, each answered on its own.
What is rebate claims validation?
Rebate claims validation is checking a payer's rebate invoice before the drug maker pays it: that each prescription is eligible under the contract, billed at the rate the contract pays, and not also a 340B, State Medicaid or previously paid claim. It is also called script-level validation because it goes down to each prescription. The output is a line-by-line view of billed, owed and variance.
What is a script scrubber?
A script scrubber is software that tests a payer's utilization file, row by row, against contract and eligibility rules before a rebate is calculated. Typical checks include plan, date, duplicate and 340B tests. It usually works beside a revenue management system, and it depends on how well its rules match each contract.
How does formulary compliance validation work?
Formulary compliance validation tests whether a plan held the position a rebate requires, such as a preferred tier with no step therapy, during the period the contract names. It compares the payer's formulary file, plan by plan and month by month, with the contract clause. A line billed at the preferred rate on a plan that moved the drug is recalculated at the rate that position earns.
What is the difference between a Part D rebate and a Medicaid rebate?
A Part D rebate is negotiated in a private contract between a maker and a plan sponsor or its PBM, usually in exchange for formulary placement. A Medicaid rebate is set by statute: for brand drugs, the greater of 23.1% of average manufacturer price or that price less Best Price, plus an inflation amount. Part D prices are excluded from Best Price, and rebates paid to State Medicaid agencies are excluded too.
What is a 340B duplicate discount?
A duplicate discount happens when one fill gets both a 340B price and a Medicaid rebate, which federal law bars under 42 USC 256b(a)(5)(A). Commercial and Part D contracts usually add their own exclusions of 340B claims, and those are contract terms. Teams test for these claims with the federal 340B database on the dispensing date and with NCPDP Submission Clarification Code 20.
How do you identify 340B claims on a rebate invoice?
Use two tests: match the dispensing pharmacy against the federal 340B database for the date of dispensing, and read the claim's Submission Clarification Code, where a value of 20 marks 340B. A database match shows the pharmacy was a contract pharmacy on that date, which may fall short of proving a 340B fill. Your contract's wording decides whether the match alone excludes the claim.
Do commercial rebates affect Medicaid Best Price?
Some do. Under 42 CFR 447.505, rebates are generally part of Best Price, but rebates to PBMs are excluded unless they relate to mail-order purchases or are designed to adjust retail or provider prices. Rebates to a health plan or HMO can count. Your government pricing team and counsel should classify each agreement.
How long does a manufacturer have to pay a Medicaid rebate invoice?
The statute says not later than 30 days after receiving the State's information, and CMS's interest page says manufacturers have 37 calendar days before interest begins, with interest starting on the 38th day from the invoice postmark. CMS has long said to pay the undisputed part on time and to identify disputes by drug code, quarter and reason.
Can a manufacturer dispute a rebate invoice after paying it?
On State Medicaid invoices, yes: CMS Release No. 27 describes paying in full on time and disputing afterward, which removes interest on the payment, and says the State must credit any reduction with interest. On commercial and Part D invoices your contract decides, including how long the window stays open. Many teams prefer to dispute before paying, because recovering a credit later can be slow.
What is gross-to-net leakage?
Gross-to-net leakage is money a drug maker pays in rebates, fees and discounts that it did not owe under its contracts or the law. It sits inside the much larger gross-to-net difference, which Drug Channels Institute estimates at $416 billion for brand drugs in 2025. No independent study publishes a leakage rate. Vendors state figures from 2% to 10%, each measuring something different.
What files do you need to validate a rebate invoice?
You need the invoice, the utilization file with one row per prescription, the agreement and every amendment, the payer's formulary files by month, the federal 340B database, State Medicaid invoices and earlier quarters' files. The NCPDP manufacturer rebate standard covers utilization, plan, formulary, market basket and reconciliation files, although many payers use their own layouts.
Can AI validate rebate claims?
AI can read unusual file layouts and contract clauses and draft dispute letters, and rule-based software can test every row. Accuracy has to be measured before you rely on it: test on your own paid invoices with planted errors, scored by error type, and count false alarms. A person should decide each dispute and sign each payment.
Does the 340B rebate pilot change rebate validation in 2027?
Perhaps for a small set of drugs. A revised federal pilot published in August 2026 is due to take effect January 1, 2027, for drugs on the Medicare negotiation lists for 2026 and 2027, and hospital groups sued in October 2026 to stop it, with a House bill to delay it. We found no ruling reported as of November 3, 2026, so check its status before planning on it. Payer rebate invoices and their checks continue either way.
23 · One-page summary
Rebate claims validation on one page: the method, the 2026 rules, readiness and terms
Print this page
In shortThe whole guide on one screen: the method, the rules as of November 2026, the readiness questions and the terms.
The method
Tie the invoice to its files; merge main and adjustment files; stop if totals differ.
Find the terms in force that quarter, each with its clause and amendment.
Test position by plan and month, using each clause's own time test.
Test each prescription: plan, dates, 340B, Medicaid, duplicates, look-back, territory, quantity.
Recalculate every line and the fee: billed, owed, variance.
A person decides each exception; one letter cites every clause; pay the undisputed amount on time.
Check the Best Price effect by channel; sign; true up the accrual; track replies.
Readiness: score 0–2 on eight questions: 0–6 explore · 7–11 pilot · 12–16 implement.
As of November 2026: Medicaid rebate cap ended January 1, 2024 · negotiated Medicare prices from January 1, 2026, 15 more January 1, 2027 · revised 340B rebate pilot set for January 1, 2027, under challenge · PBM pay delinked in Part D from January 1, 2028 · GENEROUS model launched January 2026.
14 terms
Rebate
A payment from maker to payer after the sale, on contract terms.
PBM
Pharmacy benefit manager: runs a plan's drug benefit and often negotiates rebates.
Utilization file
One row per prescription behind a rebate invoice.
Script
A prescription; "script-level" means tested one by one.
Script scrubber
Software that runs rule checks on a utilization file.
Formulary position
A drug's tier and restrictions on a plan's covered list.
Plan benefit package
One Part D plan under a sponsor's contract.
Step therapy
Requires trying another drug first; often lowers the rebate earned.
WAC
Wholesale acquisition cost: the list price.
Gross-to-net
The gap between list-price sales and what a maker keeps.
340B
A federal program that gives covered hospitals and clinics discounted drugs.
Code 20
NCPDP Submission Clarification Code value marking a 340B claim.
Best Price
The lowest eligible net price in a quarter; it feeds the Medicaid rebate.
True-up
Correcting the accrual once the invoice shows the real amount.
24 · Sources
Sources
Accessed November 2026. Regulatory status statements are as of November 2026.
Milliman, "A primer on Medicare Part D prescription drug rebates: Insights into the possible impact of the Inflation Reduction Act", September 29, 2023. milliman.com
IQVIA (L. Campbell, H. Lopez, S. Dhawan), "Deconstructing Managed Care Rebate Processing Challenges", white paper, 2023. iqvia.com
Drug Channels Institute (A. Fein), "2025 Gross-to-Net Realities at Eight" manufacturers, July 2026. drugchannels.net
National Council for Prescription Drug Programs, Access to Standards: "Manufacturer Rebates Utilization, Plan, Formulary, Market Basket, and Reconciliation Flat File Standard". ncpdp.org
Health Care Financing Administration (now CMS), Medicaid Drug Rebate Program Release No. 27 to participating manufacturers, March 5, 1997. medicaid.gov
42 CFR 447.505, Determination of best price, current text. law.cornell.edu
US Government Accountability Office, GAO-23-107056, "Medicare Part D: CMS Should Monitor Effects of Rebates on Drug Coverage and Spending", September 19, 2023. gao.gov
42 USC 1396r-8, Payment for covered outpatient drugs (Social Security Act section 1927), current text. law.cornell.edu
42 USC 256b, Limitation on prices of drugs purchased by covered entities (Public Health Service Act section 340B), current text. law.cornell.edu
42 CFR 447.509, Medicaid drug rebates, current text. law.cornell.edu
CMS, Medicare Drug Price Negotiation Program, "Selected Drugs and Negotiated Prices", current page. cms.gov
KFF (E. Williams), "Understanding the Medicaid Prescription Drug Rebate Program", March 13, 2026. kff.org
Health Resources and Services Administration, "Notice Regarding 340B Rebate Model Pilot Program", 91 FR 48883, August 3, 2026, FR Doc. 2026-15633. govinfo.gov
American Hospital Association, "AHA urges court to reject drug industry intervention in 340B rebate program case", October 21, 2026. aha.org
American Hospital Association, "AHA expresses support for House bill that would delay 340B rebate model", October 15, 2026, on H.R. 10770. aha.org
Sidley Austin, "Congress Passes Significant Federal Pharmacy Benefit Manager Reform Impacting Pharmaceutical Market", February 2026, on the Consolidated Appropriations Act, 2026. sidley.com
Federal Trade Commission, "FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients", February 4, 2026. ftc.gov
Federal Trade Commission, "FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman", July 14, 2026. ftc.gov
CMS Innovation Center, "GENEROUS Model", page modified October 14, 2026. cms.gov
42 CFR 423.120, Access to covered Part D drugs, paragraphs (e) and (f) on negative formulary changes, current text. law.cornell.edu
Centers for Medicare & Medicaid Services, "Interest Calculation for Late Rebate Payments", page updated June 10, 2026. medicaid.gov
42 CFR 447.510, Requirements for manufacturers, current text. law.cornell.edu
42 CFR 1001.952, Exceptions (the Anti-Kickback safe harbors), paragraph (h) on discounts, current text. law.cornell.edu
HHS Office of Inspector General, "Action to Delay Effective Date Consistent With Congressionally Enacted Moratorium", 88 FR 90125, December 29, 2023. govinfo.gov
45 CFR 164.514, Other requirements relating to uses and disclosures of protected health information (de-identification), current text. law.cornell.edu
15 USC 7262, Management assessment of internal controls (Sarbanes-Oxley Act section 404), current text. law.cornell.edu
FDA, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products", draft guidance, January 2025. fda.gov
Pharmaceutical Commerce, "Inside the 340B Rebate Pilot Standoff", October 22, 2026. pharmaceuticalcommerce.com
Centers for Medicare & Medicaid Services, proposed rule CMS-4214-P, 91 FR 66408, October 20, 2026. govinfo.gov
Federal Trade Commission, "Caremark Rx, Zinc Health Services, et al., In the Matter of (Insulin)", case page, File No. 221 0114, last updated July 14, 2026, read November 3, 2026. ftc.gov
Model N, "Model N Validata" solution brief, vendor document, 2022. modeln.com
Prime Therapeutics, "Notification of Medicare Part D Negative Formulary Change(s)", June 2026. primetherapeutics.com
Drug Channels Institute, "340B Hit $81 Billion in 2024 (+23%)", December 15, 2025. drugchannels.net
American Society for Health Care Engineering / AHA News, "HRSA announces 340B program sales reached $100 billion in CY 2025", July 14, 2026. ashe.org
New York State Medicaid, "NCPDP D.0 Billing Clarification for 340B Drug Claims", October 13, 2017. emedny.org
HHS Office of Inspector General, "Contract Pharmacy Arrangements in the 340B Program", OEI-05-13-00431, February 4, 2014. oig.hhs.gov
MMIT, "How Is MMIT's Contract Validation Solution Helping Pharma Manufacturers?", vendor case study, February 2025. mmitnetwork.com
Pharmaceutical Commerce, "Contract administration software market heats up with new offerings", December 17, 2013. pharmaceuticalcommerce.com
M. Litow (Kalderos), "3 steps drug manufacturers can take to mitigate revenue loss from drug rebate noncompliance", MedCity News, August 2, 2023. medcitynews.com
HHS, "Annual Civil Monetary Penalties Inflation Adjustment", 91 FR 3665, January 28, 2026 (45 CFR 102.3); HHS later announced no adjustment for 2026 (FR Doc. 2026-21524). govinfo.gov
BeOne Medicines Ltd., Form 10-K for fiscal 2025, Item 1A risk factors, filed 2026. sec.gov
Drug Channels Institute, "Gross-to-Net Bubble Hits $356B in 2024, But Growth Slows to 10-Year Low", July 15, 2025. drugchannels.net
Drug Channels Institute, "The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments", March 30, 2026. drugchannels.net
Medicare Payment Advisory Commission, staff slides on Part D direct and indirect remuneration data, April 2022 (data marked preliminary). medpac.gov
Next step
See it on your own payer invoices.
Explore the solution, or bring a sample of past rebate invoices, the contracts behind them and the formulary files, and we will reconcile them with you, every variance beside its clause.
We use essential cookies to make this site work, and cookieless, anonymised analytics to understand how it's used. "Accept all" also turns on Google Analytics, which sets cookies. Privacy policy